Head and Neck Cancer
61186372HNC3001 (OrigAMI-5): A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Details
ClinicalTrials.gov ID:
NCT07276399
Diagnosis Type:
NA
USOR Number:
- Address
,
P: